Literature DB >> 29997210

Herpes Simplex Virus 1 UL36USP Antagonizes Type I Interferon-Mediated Antiviral Innate Immunity.

Hui Yuan1,2, Jia You3, Hongjuan You4, Chunfu Zheng5,6.   

Abstract

Type I interferons (IFNs), as major components of the innate immune system, play a vital role in host resistance to a variety of pathogens. Canonical signaling mediated by type I IFNs activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway through binding to the IFN-α/β receptor (IFNAR), resulting in transcription of IFN-stimulated genes (ISGs). However, viruses have evolved multiple strategies to evade this process. Here, we report that herpes simplex virus 1 (HSV-1) ubiquitin-specific protease (UL36USP) abrogates the type I IFN-mediated signaling pathway independent of its deubiquitinase (DUB) activity. In this study, ectopically expressed UL36USP inhibited IFN-β-induced activation of ISRE promoter and transcription of ISGs, and overexpression of UL36USP lacking DUB activity did not influence this effect. Furthermore, UL36USP was demonstrated to antagonize IFN-β-induced activation of JAKs and STATs via specifically binding to the IFNAR2 subunit and blocking the interaction between JAK1 and IFNAR2. More importantly, knockdown of HSV-1 UL36USP restored the formation of JAK1-IFNAR2 complex. These findings underline the roles of UL36USP-IFNAR2 interaction in counteracting the type I IFN-mediated signaling pathway and reveal a novel evasion mechanism of antiviral innate immunity by HSV-1.IMPORTANCE Type I IFNs mediate transcription of numerous antiviral genes, creating a remarkable antiviral state in the host. Viruses have evolved various mechanisms to evade this response. Our results indicated that HSV-1 encodes a ubiquitin-specific protease (UL36USP) as an antagonist to subvert type I IFN-mediated signaling. UL36USP was identified to significantly inhibit IFN-β-induced signaling independent of its deubiquitinase (DUB) activity. The underlying mechanism of UL36USP antagonizing type I IFN-mediated signaling was to specifically bind with IFNAR2 and disassociate JAK1 from IFNAR2. For the first time, we identify UL36USP as a crucial suppressor for HSV-1 to evade type I IFN-mediated signaling. Our findings also provide new insights into the innate immune evasion by HSV-1 and will facilitate our understanding of host-virus interplay.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HSV-1; IFNAR2; UL36USP; type I IFN-mediated signaling

Mesh:

Substances:

Year:  2018        PMID: 29997210      PMCID: PMC6146802          DOI: 10.1128/JVI.01161-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor.

Authors:  Abu Z M Saleh; Aaron T Fang; Allison E Arch; Divas Neupane; Ashraf El Fiky; John J Krolewski
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

2.  Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.

Authors:  Junji Xing; Shuai Wang; Rongtuan Lin; Karen L Mossman; Chunfu Zheng
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 3.  Interferon signalling network in innate defence.

Authors:  Akinori Takaoka; Hideyuki Yanai
Journal:  Cell Microbiol       Date:  2006-06       Impact factor: 3.715

4.  Autocatalytic activity of the ubiquitin-specific protease domain of herpes simplex virus 1 VP1-2.

Authors:  M Bolstad; F Abaitua; C M Crump; P O'Hare
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

5.  The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network.

Authors:  H Jia; L Song; Q Cong; J Wang; H Xu; Y Chu; Q Li; Y Zhang; X Zou; C Zhang; Y E Chin; X Zhang; Z Li; K Zhu; B Wang; H Peng; Z Hou
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

6.  Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex.

Authors:  Shin-ichi Yokota; Hiroyuki Saito; Toru Kubota; Noriko Yokosawa; Ken-ichi Amano; Nobuhiro Fujii
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

7.  Herpes Simplex Virus 1 Ubiquitin-Specific Protease UL36 Abrogates NF-κB Activation in DNA Sensing Signal Pathway.

Authors:  Ruijie Ye; Chenhe Su; Haiyan Xu; Chunfu Zheng
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

8.  Cleavage specificity of the UL48 deubiquitinating protease activity of human cytomegalovirus and the growth of an active-site mutant virus in cultured cells.

Authors:  Eui Tae Kim; Se Eun Oh; Yun-Ok Lee; Wade Gibson; Jin-Hyun Ahn
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

9.  Herpes simplex virus 1 counteracts viperin via its virion host shutoff protein UL41.

Authors:  Guanghui Shen; Kezhen Wang; Shuai Wang; Mingsheng Cai; Mei-li Li; Chunfu Zheng
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

10.  Comprehensive characterization of interaction complexes of herpes simplex virus type 1 ICP22, UL3, UL4, and UL20.5.

Authors:  Junji Xing; Shuai Wang; Fusen Lin; Weiwei Pan; Chang-Deng Hu; Chunfu Zheng
Journal:  J Virol       Date:  2010-12-08       Impact factor: 6.549

View more
  18 in total

1.  Pseudorabies Virus Inhibits Type I and Type III Interferon-Induced Signaling via Proteasomal Degradation of Janus Kinases.

Authors:  Yue Yin; Nicolás Romero; Herman W Favoreel
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

Review 2.  The Race between Host Antiviral Innate Immunity and the Immune Evasion Strategies of Herpes Simplex Virus 1.

Authors:  Huifang Zhu; Chunfu Zheng
Journal:  Microbiol Mol Biol Rev       Date:  2020-09-30       Impact factor: 11.056

Review 3.  Host Innate Immune Response and Viral Immune Evasion During Alphaherpesvirus Infection.

Authors:  Krystal K Lum; Ileana M Cristea
Journal:  Curr Issues Mol Biol       Date:  2021-02-28       Impact factor: 2.081

4.  Inhibition of Antiviral Innate Immunity by Avibirnavirus VP3 via Blocking TBK1-TRAF3 Complex Formation and IRF3 Activation.

Authors:  Tingjuan Deng; Boli Hu; Xingbo Wang; Lulu Lin; Jianwei Zhou; Yuting Xu; Yan Yan; Xiaojuan Zheng; Jiyong Zhou
Journal:  mSystems       Date:  2021-05-11       Impact factor: 6.496

5.  HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection.

Authors:  Chiranjeevi Bodda; Line S Reinert; Stefanie Fruhwürth; Timmy Richardo; Chenglong Sun; Bao-Cun Zhang; Maria Kalamvoki; Anja Pohlmann; Trine H Mogensen; Petra Bergström; Lotta Agholme; Peter O'Hare; Beate Sodeik; Mads Gyrd-Hansen; Henrik Zetterberg; Søren R Paludan
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

Review 6.  Herpes Simplex Virus Type 1 Interactions with the Interferon System.

Authors:  Kevin Danastas; Monica Miranda-Saksena; Anthony L Cunningham
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

Review 7.  Inflammation, Infectious Triggers, and Parkinson's Disease.

Authors:  Elisa Caggiu; Giannina Arru; Sepideh Hosseini; Magdalena Niegowska; GianPietro Sechi; Ignazio Roberto Zarbo; Leonardo A Sechi
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

8.  Herpes Simplex Virus Type 1-Encoded miR-H2-3p Manipulates Cytosolic DNA-Stimulated Antiviral Innate Immune Response by Targeting DDX41.

Authors:  Yongzhong Duan; Jieyuan Zeng; Shengtao Fan; Yun Liao; Min Feng; Lichun Wang; Ying Zhang; Qihan Li
Journal:  Viruses       Date:  2019-08-15       Impact factor: 5.048

Review 9.  A Tug of War: DNA-Sensing Antiviral Innate Immunity and Herpes Simplex Virus Type I Infection.

Authors:  Yingying Lin; Chunfu Zheng
Journal:  Front Microbiol       Date:  2019-11-26       Impact factor: 5.640

10.  Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases.

Authors:  Soham Gupta; Päivi Ylä-Anttila; Tatyana Sandalova; Adnane Achour; Maria G Masucci
Journal:  Front Immunol       Date:  2020-03-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.